Cancer Medicine 2017; 6(11):2515--2522

Introduction {#cam41207-sec-0001}
============

A world‐epidemic, particularly in the United States [1](#cam41207-bib-0001){ref-type="ref"}, [2](#cam41207-bib-0002){ref-type="ref"}, [3](#cam41207-bib-0003){ref-type="ref"}, obesity has been linked with an increased risk for development of breast cancer, and possibly worse outcomes when compared to nonobese patients at the time of diagnosis [4](#cam41207-bib-0004){ref-type="ref"}, [5](#cam41207-bib-0005){ref-type="ref"}, [6](#cam41207-bib-0006){ref-type="ref"}, [7](#cam41207-bib-0007){ref-type="ref"}, [8](#cam41207-bib-0008){ref-type="ref"}, [9](#cam41207-bib-0009){ref-type="ref"}, [10](#cam41207-bib-0010){ref-type="ref"}.

Moreover, it has been suggested that women tend to gain weight after breast cancer diagnosis, as a result of decreased energy expenditure, depression, hormonal imbalance, and changes in body composition [11](#cam41207-bib-0011){ref-type="ref"}, [12](#cam41207-bib-0012){ref-type="ref"}, [13](#cam41207-bib-0013){ref-type="ref"}, [14](#cam41207-bib-0014){ref-type="ref"}, [15](#cam41207-bib-0015){ref-type="ref"}. As demonstrated previously, increase in weight within the first year after breast cancer diagnosis may potentially lead to worse outcomes, although data are conflicting [16](#cam41207-bib-0016){ref-type="ref"}, [17](#cam41207-bib-0017){ref-type="ref"}, [18](#cam41207-bib-0018){ref-type="ref"}, [19](#cam41207-bib-0019){ref-type="ref"}, [20](#cam41207-bib-0020){ref-type="ref"}. Weight variation can be further exacerbated when patients undergo chemotherapy for early‐stage breast cancer [20](#cam41207-bib-0020){ref-type="ref"}, [21](#cam41207-bib-0021){ref-type="ref"}. It has been suggested that overweight and obese patients who undergo neoadjuvant chemotherapy may be less likely to achieve a pathologic complete response (pCR) [22](#cam41207-bib-0022){ref-type="ref"}. Additionally, obesity may interfere with drug metabolism, contributing to lower response rates [23](#cam41207-bib-0023){ref-type="ref"}, [24](#cam41207-bib-0024){ref-type="ref"}.

Despite some efforts to address this matter, how weight change during adjuvant chemotherapy, when observed, may affect long‐term survival outcomes remains widely unclear, particularly regarding the possible transient nature in which this weight variation may occur. The purpose of our study was to examine how patients' weight variations that occur during adjuvant chemotherapy for early‐stage breast cancer behave 1 year after the last infusion and how weight gain during treatment influences long‐term survival outcomes.

Materials and Methods {#cam41207-sec-0002}
=====================

Under a protocol approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (UTMDACC, Houston, TX), we queried the UTMDACC prospectively collected Breast Cancer Management System Database for patients that met the following inclusion criteria: early‐stage (I--III) breast cancer diagnosis that received a third‐generation adjuvant chemotherapy (anthracycline and/or taxane‐based) regimen.

Data collection {#cam41207-sec-0003}
---------------

Data were extracted for patient demographics (race, age, and menopausal status), treatment data (chemotherapy and endocrine treatment, surgery type and surgical margin, and adjuvant radiation delivery), and tumor characteristics (clinical stage, estrogen receptor \[ER\], and progesterone receptor \[PR\], combined as hormone receptor status, histologic grade, and HER‐2 status). Smoking status was not available for the majority of patients and was not included. Follow‐up information for patients in the Breast Cancer Management System database is obtained every 2 years by direct review of the medical records and linkage to the MDACC Tumor Registry, which mails annual follow‐up letters to each patient registered at MDACC known to be alive to determine the patient\'s clinical status. Recurrence data were obtained and broken down to locoregional, distant, and contralateral recurrence. The MDACC Tumor Registry checks the Social Security Death Index and the Texas Bureau of Vital Statistics for the status of patients who do not respond to the letters.

Body mass index (BMI) was calculated by dividing weight (kg) by the square of the height (m^2^) [25](#cam41207-bib-0025){ref-type="ref"}, assessed by nursing staff during follow‐up visits. BMI was calculated at diagnosis, first chemotherapy date, last chemotherapy date, and 1 year after last chemotherapy date. Patients were grouped into obese (BMI ≥ 30 kg/m^2^), overweight (BMI between 25 and 30 kg/m^2^), and normal/underweight (BMI \< 25 kg/m^2^). Change in BMI was computed by subtracting prechemotherapy value from postchemotherapy, and postchemotherapy value from 1 year postchemotherapy. Patients' BMI variation from start to end of adjuvant chemotherapy was separated in three groups: (1), \>0.5 kg/m^2^ loss; (2), \>0.5 kg/m^2^ gain; and (3), stable BMI (maintained ± 0.5 kg/m^2^).

Statistical analysis {#cam41207-sec-0004}
--------------------

Patient baseline characteristics were compared between three BMI variations during chemotherapy (three groups) utilizing Kruskal‐Wallis test for continuous variables and Chi‐square test or Fisher\'s exact test for categorical variables.

Five survival outcome variables since surgery, including progression‐free survival (PFS), distant recurrence‐free survival (DMFS), locoregional recurrence‐free survival (LRFS), contralateral breast cancer‐free survival (CLBCFS), and overall survival (OS), were obtained. Those without an event were censored at the time of last follow‐up. Univariate Cox regression analyses were performed. Factors with univariate *P*‐value of less than 0.15 were initially included in a multivariable model, then further reduced by backward elimination (*α* \< 0.1). The same analysis was performed in the subgroup of postmenopausal women. The Bonferroni correction model was applied to account for multiple testing, in which the type I error rate of 0.05 was equally split between the five endpoints (i.e., 0.01).

Results {#cam41207-sec-0005}
=======

We identified 2356 patients that met our study criteria, treated between 2004 and 2015. Due to unreliable weight/height abstraction, 358 patients were excluded, resulting in 1998 total patients included in this analysis. The median follow‐up time was 7.1 years (95% CI, 6.9--7.2).

The majority of patients had ductal carcinoma histology and were hormone receptor‐positive and HER‐2‐negative. Similar number of patients either lost or gained more than 0.5 kg/m^2^, or maintained their BMI. Women over 50 years old and postmenopausal were more likely to lose weight during adjuvant chemotherapy, whereas women under 30 years old gained more weight (*P *\<* *0.001). At 1 year postchemotherapy, patients tended to return to their original weight (correlation between BMI change during chemotherapy and BMI change from the end of chemo to 1 year postchemotherapy: *ρ *= −0.3, *P *\<* *0.001). Notably, patients that gained more than 0.5 kg/m^2^ during chemotherapy tended to lose more than half of the weight during the year postchemotherapy (*ρ *= −0.58; *P *\<* *0.001). Patients that gained more than 0.5 kg/m^2^ had their weight increased by an average of 4.12 kg from first to last chemotherapy date (SD = 3.01) and lost 0.51 kg from the first day of chemotherapy to 1 year past the last chemotherapy date (SD = 5.15). Full baseline characteristics are displayed in Table [1](#cam41207-tbl-0001){ref-type="table-wrap"}.

###### 

Baseline characteristics according to BMI change group

  Variable                                                                             BMI Change (chemo start to end)   *P*‐value                   
  ------------------------------------------------------------------------------------ --------------------------------- ------------- ------------- ---------
  Age at diagnosis                                                                                                                                   
  \<30                                                                                 9 (1.4%)                          8 (1.2%)      18 (2.5%)     \<0.001
  30--40                                                                               46 (7.4%)                         82 (12.5%)    142 (19.8%)   
  40--50                                                                               167 (26.8%)                       227 (34.5%)   273 (38%)     
  \>50                                                                                 400 (64.3%)                       341 (51.8%)   285 (39.7%)   
  Postmenopausal                                                                       426 (68.5%)                       378 (57.5%)   342 (47.7%)   \<0.001
  BMI at diagnosis                                                                                                                                   
  \<18                                                                                 2 (0.3%)                          11 (1.7%)     6 (0.8%)      \<0.001
  18--25                                                                               160 (25.7%)                       283 (43%)     276 (38.4%)   
  25--30                                                                               186 (29.9%)                       184 (28%)     234 (32.6%)   
  30--35                                                                               132 (21.2%)                       106 (16.1%)   131 (18.2%)   
  35--40                                                                               83 (13.3%)                        51 (7.8%)     45 (6.3%)     
  \>40                                                                                 59 (9.5%)                         23 (3.5%)     26 (3.6%)     
  Weight change during chemotherapy[a](#cam41207-note-0003){ref-type="fn"}(Mean, SD)   −4.4 ± 3.4                        0.02 ± 0.7    4.1 ± 3.0     \<0.001
  Weight change post chemotherapy[b](#cam41207-note-0004){ref-type="fn"} (Mean, SD)    1.9 ± 6.1                         0.4 ± 4.0     −0.5 ± 5.1    \<0.001
  Grade                                                                                                                                              
  I--II                                                                                280 (45.2%)                       319 (48.8%)   310 (43.4%)   0.127
  III                                                                                  339 (54.8%)                       335 (51.2%)   405 (56.6%)   
  Hormone receptor status                                                                                                                            
  Positive                                                                             456 (73.3%)                       511 (77.7%)   548 (76.3%)   0.178
  Negative                                                                             166 (26.7%)                       147 (22.3%)   170 (23.7%)   
  Lymph node status                                                                                                                                  
  Positive                                                                             196 (31.5%)                       186 (28.3%)   277 (38.6%)   \<0.001
  Negative                                                                             426 (68.5%)                       471 (71.7%)   441 (61.4%)   
  Histology                                                                                                                                          
  Ductal                                                                               500 (80.4%)                       519 (78.9%)   604 (84.1%)   0.078
  Lobular                                                                              63 (10.1%)                        69 (10.5%)    49 (6.8%)     
  Other                                                                                59 (9.5%)                         70 (10.6%)    65 (9.1%)     
  Her‐2 status                                                                                                                                       
  Positive                                                                             58 (9.3%)                         91 (13.8%)    130 (18.1%)   \<0.001
  Negative                                                                             564 (90.7%)                       567 (86.2%)   588 (81.9%)   
  BRCA                                                                                                                                               
  Positive                                                                             20 (14.7%)                        22 (13.3%)    26 (12.4%)    0.824
  Negative                                                                             116 (85.3%)                       143 (86.7%)   184 (87.6%)   

Hormone receptor includes estrogen and progesterone receptor. BMI, body mass index.

Change from first chemotherapy date to last chemotherapy date.

Change from first chemotherapy date to 1 year after the last date.
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BMI and survival outcomes {#cam41207-sec-0006}
-------------------------

On univariate analysis, BMI variation did not affect survival outcomes, except for worse LRFS in the group with BMI increase of more than 0.5 kg/m^2^ (Table [2](#cam41207-tbl-0002){ref-type="table-wrap"}). On multivariate analysis, more than 0.5 kg/m^2^ increase in BMI was only found to be associated with increased risk for locoregional recurrence (HR, 2.53; 95% CI, 1.18--5.45; *P *=* *0.017), adjusting for grade, stage, and radiation delivery (Table [3](#cam41207-tbl-0003){ref-type="table-wrap"}). This finding was marginally significant after reducing the alpha to 0.01, as an adjustment to multiple testing bias. To further elucidate the impact of weight gain on LRFS, we divided the "0.5 kg/m^2^ gain" category into "0.5--2.0 kg/m^2^" gain" and "\>2 kg/m^2^ gain". Interestingly, we found that LRFS was only marginally worse in the "0.5--2 kg/m^2^" group (HR, 2.684; 95% CI, 1.219--5.909; *P = *0.0142), but not for greater than 2 kg/m^2^. In absolute numbers, however, the clinical impact was low (5‐year LRFS: 99% vs. 97% in the \>0.5 kg/m2 gain vs. \<0.5 kg/m^2^ gain), with only 46 events among 1998 patients. Median time to locoregional recurrence was not reached yet.

###### 

Univariate analysis of body mass index change during adjuvant chemotherapy and survival outcomes

                            HR     95% CI   *P*‐value   5‐YS    
  ------------------------- ------ -------- ----------- ------- ------
  *PFS*                                                         
  BMI change during chemo                               0.347   
  \>0.5 loss kg/m^2^        1.06   0.72     1.57        0.752   94%
  Maintain ± 0.5 kg/m^2^    1.00                                94%
  \>0.5 gain kg/m^2^        1.28   0.90     1.84        0.171   93%
  *LRFS*                                                        
  BMI change during chemo                               0.024   
  \>0.5 kg/m^2^ loss        1.33   0.55     3.22        0.523   98%
  Maintain ± 0.5 kg/m^2^    1.00                                99%
  \>0.5 gain kg/m^2^        2.59   1.21     5.56        0.014   97%
  *OS*                                                          
  BMI change during chemo                               0.384   
  \>0.5 loss kg/m^2^        1.29   0.81     2.03        0.278   95%
  Maintain ± 0.5 kg/m^2^    1.00                                97%
  \>0.5 gain kg/m^2^        1.34   0.87     2.08        0.186   95%
  *DMFS*                                                        
  BMI change during chemo                               0.698   
  \>0.5 loss kg/m^2^        1.06   0.70     1.60                95%
  Maintain ± 0.5 kg/m^2^    1.00                                95%
  \>0.5 gain kg/m^2^        1.18   0.80     1.73                94%
  *CLBCFS*                                                      
  BMI change during chemo                               0.133   
  \>0.5 loss kg/m^2^        0.21   0.05     0.96        0.045   100%
  Maintain ± 0.5 kg/m^2^    1.00                                98%
  \>0.5 gain kg/m^2^        0.74   0.29     1.86        0.518   99%

BMI, body mass index; PFS, progression‐free survival; DMFS, distant metastasis‐free survival; LRFS, locoregional recurrence‐free survival; CLBCFS, contra lateral breast cancer‐free survival; OS, overall survival; 5‐YS, 5‐year survival HR, hazard ratio; CI, confidence interval.
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###### 

Univariate and multivariate analysis of locoregional recurrence‐free survival

                           Univariate analysis   Multivariate analysis[a](#cam41207-note-0007){ref-type="fn"}                                         
  ------------------------ --------------------- -------------------------------------------------------------- ------- ------- ------ ------ ------- -------
  BMI at diagnosis                                                                                                      0.184                         
  \<18                     2.40                  0.32                                                           18.28   0.398                         
  18--25                   1.00                                                                                                                       
  25--30                   0.95                  0.43                                                           2.10    0.902                         
  30--35                   1.13                  0.48                                                           2.70    0.778                         
  35--40                   2.71                  1.17                                                           6.27    0.020                         
  \>40                     0.99                  0.22                                                           4.35    0.987                         
  Age                                                                                                                   0.549                         
  \<30                     1.56                  0.21                                                           11.61   0.662                         
  30--40                   1.61                  0.74                                                           3.49    0.232                         
  40--50                   0.90                  0.45                                                           1.79    0.761                         
  \>50                     1.00                                                                                                                       
  Grade                                                                                                                 0.017                         0.010
  I                        0.00                                                                                         0.986   0.00                  0.986
  II                       0.36                  0.18                                                           0.73    0.004   0.34   0.17   0.68    0.002
  III                      1.00                                                                                                 1.00                  
  Hormone status (ER/PR)                                                                                                                              
  Positive                 0.62                  0.34                                                           1.16    0.127                         
  Negative                 1.00                                                                                                                       
  Her‐2 status                                                                                                                                        
  Positive                 1.95                  0.99                                                           3.86    0.055                         
  Negative                 1.00                                                                                                                       
  Stage                                                                                                                 0.060                         0.023
  1                        1.00                                                                                                 1.00                  
  2                        2.70                  1.185                                                          6.14    0.018   2.97   1.30   6.77    0.010
  3                        2.44                  0.884                                                          6.73    0.085   3.55   1.24   10.16   0.018
  Tumor size (in cm)                                                                                                    0.231                         
  0--2                     1.00                                                                                                                       
  2.1--5                   1.67                  0.91                                                           3.08    0.100                         
  \>5                      1.79                  0.53                                                           6.08    0.352                         
  Adjuvant radiation                                                                                                                                  
  Yes                      0.55                  0.31                                                           0.99    0.047   0.53   0.28   0.99    0.045
  No                       1.00                                                                                                                       
  Type of surgery                                                                                                                                     
  Mastectomy               0.74                  0.29                                                           1.88    0.532                         
  Lumpectomy               1.00                                                                                                                       
  Surgical margin                                                                                                                                     
  Positive                 0.66                  0.09                                                           4.79    0.680                         
  Negative                 1.00                                                                                                                       

BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; LRFS, locoregional recurrence‐free survival; HR, hazard ratio; CI, confidence interval.

Factors with univariate *P *\< 0.15 were initially included in a multivariable model then further reduced by backward elimination (α \< 0.1).

John Wiley & Sons, Ltd

Factors associated with worse OS were age \<30 years old (HR, 2.56; 95% CI, 1.02--6.39; *P *=* *0.045), tumor stages 2 and 3, comparing to 1 (HR, 1.69; 95% CI, 1.04--2.73; *P* = 0.034 and HR, 4.65; 95% CI, 2.79--7.76; *P *\<* *0.001), and tumor grade III (vs. I--II; HR, 1.99; 95% CI, 1.29--3.09; *P *=* *0.002; Table [4](#cam41207-tbl-0004){ref-type="table-wrap"}). Five‐year OS was similar between groups (96% overall, Fig. [1](#cam41207-fig-0001){ref-type="fig"}).

###### 

Univariate and multivariate analysis of risk factors for overall survival

                            Univariate analysis   Multivariate analysis[a](#cam41207-note-0009){ref-type="fn"}                                         
  ------------------------- --------------------- -------------------------------------------------------------- ------ --------- ------ ------ ------ ---------
  BMI at diagnosis                                                                                                      0.353                          
  \<18                      1.44                  0.35                                                           5.92   0.616                          
  18--25                    1.00                                                                                                                       
  25--30                    0.77                  0.48                                                           1.22   0.267                          
  30--35                    0.91                  0.54                                                           1.53   0.728                          
  35--40                    1.45                  0.82                                                           2.57   0.197                          
  \>40                      1.36                  0.67                                                           2.78   0.398                          
  Age                                                                                                                   0.011                          0.035
  \<30                      2.91                  1.17                                                           7.23   0.021     2.56   1.02   6.40   0.044
  30--40                    1.41                  0.874                                                          2.27   0.160     1.22   0.76   1.98   0.407
  40--50                    0.74                  0.480                                                          1.13   0.162     0.72   0.47   1.12   0.136
  \>50                      1.00                                                                                                  1.00                 
  Grade                                                                                                                                                
  I--II                     1.00                                                                                                  1.00                 
  III                       2.23                  1.51                                                           3.30   \<0.001   1.95   1.26   3.03   0.003
  Hormone status (ER/PR)                                                                                                                               
  Positive                  0.53                  0.37                                                           0.77   0.001     0.62   0.41   0.94   0.024
  Negative                  1.00                                                                                                  1.00                 
  Her‐2 status                                                                                                                                         
  Positive                  1.01                  0.61                                                           1.67   0.96                           
  Negative                  1.00                                                                                                                       
  Stage                                                                                                                 \<0.001                        \<0.001
  1                         1.00                                                                                                  1.00                 
  2                         1.49                  0.92                                                           2.40   0.101     1.69   1.04   2.73   0.033
  3                         3.81                  2.31                                                           6.29   \<0.001   4.67   2.80   7.78   \<0.001
  Tumor size (in cm)                                                                                                    0.001                          
  0--2                      1.00                                                                                                                       
  2.1--5                    1.69                  1.16                                                           2.46   0.007                          
  \>5                       3.10                  1.67                                                           5.73   \<0.001                        
  BMI change during chemo                                                                                               0.384                          
  \>0.5 loss                1.29                  0.81                                                           2.03   0.278                          
  Maintain ± 0.5            1.00                                                                                                                       
  \>0.5 gain                1.34                  0.87                                                           2.08   0.186                          

BMI: body mass index; ER: estrogen receptor; PR: progesterone receptor; HR: hazard ratio; CI, confidence interval.

Factors with univariate *P *\< 0.15 were initially included in a multivariable model then further reduced by backward elimination (*α* \< 0.1).
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![Kaplan‐Meier survival curves divided by BMI variation over time: (A) Locoregional recurrence‐free survival; (B) Overall survival.](CAM4-6-2515-g001){#cam41207-fig-0001}

BMI and survival outcomes---postmenopausal subgroup {#cam41207-sec-0007}
---------------------------------------------------

Among the 1146 patients that were postmenopausal, BMI increase by more than 0.5 kg/m^2^ was again only found to be associated with increased risk for locoregional recurrence on multivariate analysis (HR, 3.77, 95% CI, 1.24--11.45, *P *=* *0.019), adjusting for HER‐2 status.

Discussion {#cam41207-sec-0008}
==========

Our study was the largest cohort to our knowledge assessing weight specifically during adjuvant chemotherapy. We demonstrated that patients could equally gain, lose or maintain their weight throughout chemotherapy treatment, and, more importantly, that the weight variation seems to be transient in nature and tended to return to the patients' baseline values after 1 year of chemotherapy completion. We also demonstrated that an increase in BMI by more than 0.5 kg/m^2^ during adjuvant chemotherapy for early‐stage breast cancer is associated with increased risk for locoregional recurrence only, though the clinical and statistical significance were marginal.

Previous reports have shown that weight gain is a common feature after breast cancer diagnosis and during chemotherapy [11](#cam41207-bib-0011){ref-type="ref"}, [12](#cam41207-bib-0012){ref-type="ref"}, [13](#cam41207-bib-0013){ref-type="ref"}, [16](#cam41207-bib-0016){ref-type="ref"}, [20](#cam41207-bib-0020){ref-type="ref"}, [21](#cam41207-bib-0021){ref-type="ref"}. The interchangeable nature of how chemotherapy and weight variation may affect one another, however, is unclear. Obesity may have a negative impact on chemotherapy efficacy, as well as patients that receive chemotherapy might have their weight further increased during treatment. This reflects on the conflicting results reported on whether weight gain after breast cancer diagnosis influences survival outcomes [16](#cam41207-bib-0016){ref-type="ref"}, [17](#cam41207-bib-0017){ref-type="ref"}, [18](#cam41207-bib-0018){ref-type="ref"}, [19](#cam41207-bib-0019){ref-type="ref"}, [20](#cam41207-bib-0020){ref-type="ref"}. Litton et al. [22](#cam41207-bib-0022){ref-type="ref"} reported a lower rate of pCR after neoadjuvant chemotherapy in obese and overweight women, advocating for lower efficacy of therapy in this population set. Kogawa et al. [26](#cam41207-bib-0026){ref-type="ref"}, however, found higher rates of pCR in patients that increased their weight during neoadjuvant therapy. Kroenke et al. [16](#cam41207-bib-0016){ref-type="ref"} demonstrated elevated risk of breast cancer death for nonsmoking patients who gained 0.5 kg/m^2^ or more after ≥12 months from diagnosis during follow‐up, compared with women who maintained their weight. Similarly, Camoriano et al. [20](#cam41207-bib-0020){ref-type="ref"} found worse overall survival for women gaining more versus less than median weight after diagnosis. None of the aforementioned studies, however, assess weight gain specifically during the period of adjuvant therapy.

The findings of our study provide some insight on how chemotherapy may influence women\'s metabolism and prognosis. Chemotherapy can affect a patient\'s well‐being by releasing proinflammatory cytokines, decreasing energy expenditure, disrupting patients' sleep, and hypothalamic‐pituitary‐adrenal axis, as well as by causing mood and emotional disorders [27](#cam41207-bib-0027){ref-type="ref"}, [28](#cam41207-bib-0028){ref-type="ref"}, [29](#cam41207-bib-0029){ref-type="ref"}, [30](#cam41207-bib-0030){ref-type="ref"}, [31](#cam41207-bib-0031){ref-type="ref"}. As seen in our study, this can affect a patient\'s BMI as both weight gain or loss during this period (Table [1](#cam41207-tbl-0001){ref-type="table-wrap"}). Due to the limited time of treatment in this setting, usually between 3 and 6 months, these changes can be transient. As evidence of this, we found a moderate negative correlation between BMI increase during chemotherapy and subsequent decrease in the year succeeding the last dose of chemotherapy (*ρ *= −0.58; *P *\<* *0.001). As a consequence, except for marginally worse LRFS in patients gaining more than 0.5 kg/m^2^ in BMI, survival outcomes were not significantly affected by weight variation during this specific period.

In light of this, one could postulate two hypotheses: (1) if there is an increased risk in survival outcomes due to increase in BMI during adjuvant therapy, this risk may be mitigated by losing the weight during the year after treatment discontinuation; or (2) due to the transient nature of this weight behavior, the risk is not clinically significant.

Still, we observed an increased rate of locoregional recurrence with a BMI increase of more than 0.5 kg/m^2^. This risk was similar in the postmenopausal subgroup. It is unclear whether changes in body composition may lead to alterations in the breast stroma, both histologically and at the molecular level. Additionally, it is known that obesity is associated with higher systemic body oxidative stress and inflammatory biomarkers [32](#cam41207-bib-0032){ref-type="ref"}, [33](#cam41207-bib-0033){ref-type="ref"}, resulting in increased acute toxicity to radiation therapy [34](#cam41207-bib-0034){ref-type="ref"}, [35](#cam41207-bib-0035){ref-type="ref"}. How radiation\'s efficacy in breast cancer is affected by obesity, however, has not been studied. Nonetheless, this finding has minor clinical significance, particularly after splitting the group into two categories of weight gain (0.5--2.0 and \>2.0 kg/m^2^) and correcting for multiple testing bias, though this could be justified by the overall low absolute number of events in this cohort.

Our study had several limitations. Its retrospective nature, albeit involving a large cohort of patients, warrants caution in data interpretation. We had incomplete data of patients' smoking status, which has been shown to potentially influence outcomes when accounted for [16](#cam41207-bib-0016){ref-type="ref"}. Additionally, there is no clear guideline for appropriate cutoff selection of BMI change in this context, although 0.5 kg/m^2^ has been reported previously [16](#cam41207-bib-0016){ref-type="ref"}. Also, by excluding patients that received neoadjuvant therapy, in order to standardize the sequence of treatments, we may have excluded patients with more aggressive biology that required upfront systemic therapy, although the rate of triple‐negative breast cancer patients in our cohort was appropriate. The unusually low number of events overall in this study may have contributed to the absence of more significant findings, as well as the previously reported association between obesity at diagnosis and worse outcomes that were not reproduced in our study.

In conclusion, our study demonstrated that weight variation during adjuvant chemotherapy for early‐stage breast cancer may occur as both weight gain and weight loss in a balanced manner. Furthermore, this variation seems to be transient in nature and does not appear to significantly influence recurrence rates and overall survival.
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